Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

The company said the move demonstrates the board of directors' confidence in the potential of its PARP1/2 inhibitor in ovarian cancer.

Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Eikon is pursuing a number of clinical-stage programs including EIK1001, which is currently in Phase III testing for advanced melanoma.

Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.

The funding, led by existing and new investors, is expected to support Eikon’s efforts to integrate advanced computing, ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Decitabine (DAC), a well-recognized DNA ...

Eikon Therapeutics has added to its already copious cash reserves with a $351 million fourth-round financing to fund a ...

Allarity has consistently maintained that these claims were without merit. The case against all defendants has been dismissed with each party bearing its own legal costs and fees. No settlement or ...

Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, today ...